Adjuvant therapy and long-term management of differentiated thyroid carcinoma.
As with most therapies for differentiated thyroid carcinoma, there is little consensus about optimal use of postoperative adjuvant therapies or long-term follow-up strategies. However, an increasing body of data indicates that most patients can benefit from postoperative radioiodine ablation followed by thyroid hormone suppression therapy. An approach to long-term monitoring and therapy is provided, including the use of strategies dependent upon the extent of the patient's initial disease.
Sherman
S I
SI
Section of Endocrine Neoplasia and Hormonal Disorders, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA. sisherma@mdanderson.org
D013956:Antithyroid Agents / Q000627:therapeutic use; D002277:Carcinoma / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D018714:Radiotherapy, Adjuvant; D013964:Thyroid Neoplasms / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*
D013956:Antithyroid Agents